ICR launches ‘Darwinian’ cancer drug programme
The programme is to be launched in a £75 million state-of-the-art global centre of expertise in anti-evolution therapies in London.
Read More
Tag: anti-evolution therapies
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
